Statement from Breakthrough T1D, Formerly JDRF, on the Recently Announced Results of Medicare Drug Price Negotiations 

People with type 1 diabetes need insulin to live, and insulin affordability remains a critical concern. With the announced negotiated insulin price, we remain focused on ensuring that everyone who needs it has access to the products, Novolog and Fiasp, that were combined for the purposes of negotiation. We applaud the continued focus on insulin affordability and Health and Human Services’ (HHS) efforts to lower insulin costs for Medicare enrollees with diabetes. We’ll continue to work with HHS and other stakeholders to ensure that everyone, regardless of insurance status, has access to low-cost, affordable insulin and that policies continue to support innovation and the development of newer and better insulins.